azd2115

AZD2115 is a small molecule drug developed by AstraZeneca for the treatment of respiratory diseases, primarily chronic obstructive pulmonary disease (COPD). It is a bifunctional molecule known as a MABA (muscarinic antagonist and beta2-agonist), combining muscarinic acetylcholine receptor M3 antagonism with beta-2 adrenergic receptor agonism in a single compound. This dual mechanism aims to provide bronchodilation through two complementary pathways, potentially improving lung function and symptom control in COPD patients. AZD2115 has been evaluated in multiple Phase 1 and Phase 2 clinical trials using inhaled administration via nebulizer solution[1][2][6][7].